5.33 USD
▲+0.15+1.52%
2026-08-03
市值
$873.28M
市盈率
—
EPS
-1.19
股息率
—
52 周区间
2.03 – 7.18
成交量
2.56M
Beta
1.17
目标价
13.56
52W 低 2.0352W 高 7.18
价格走势
公司简介
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase...